Sign In
Buy PFE
$25.69
+0.335 (+1.32%)
At Close: Jun 04, 2026
Pfizer Just Reminded Investors Why You Should Never Count Its Stock Out
04:00am, Tuesday, 30'th Sep 2025
Pfizer (PFE 0.32%)'s stock just can't seem to get out of a tailspin. It faces question marks about its future growth, and investors have effectively given up on it.
Pfizer Is Likely To Pass The Drug Import Tariff Stress Test
03:16pm, Monday, 29'th Sep 2025
President Trump's new 100% tariff on imported drugs creates a major new risk for the pharma sector. While competitors announce flashy, multi-billion-dollar U.S. investment plans, Pfizer appears vague
3 Of My Favorite Biotech Stocks Under $10
01:15pm, Monday, 29'th Sep 2025
Today, I am highlighting three biotech stocks I like in the current market that are trading at under $10.00 a share. The options on these stocks are also lucrative and liquid, making them well-suited
Here is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending Stock
10:01am, Monday, 29'th Sep 2025
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
3 High-Yield Dividend Stocks to Buy Now for a Lifetime of Passive Income
03:43am, Monday, 29'th Sep 2025
Investors seeking passive income sources that grow steadily have a few interesting options to choose from right now. Shares of Brookfield Infrastructure Corp. (BIPC 2.58%), Realty Income (O 0.83%), an
Why Pfizer's Post-COVID Future Looks Brighter Than Ever
01:28pm, Sunday, 28'th Sep 2025
It's been a rough few years to be a Pfizer (PFE 0.68%) shareholder. Shares of the big pharma stock are down about 61% from a peak they set in late 2021.
BridgeBio, Up 80% This Year, Just Unveiled Promising News For Its Pfizer Rival
11:15am, Sunday, 28'th Sep 2025
BridgeBio Pharma said Sunday its heart-disease drug, Attruby, cut the risk of death almost in half in an exploratory study.
Down 55%, Should You Buy the Dip on Pfizer?
10:58am, Sunday, 28'th Sep 2025
Pfizer (PFE 0.64%) has a huge 7.1% dividend yield. That certainly compares favorably to the broader market's 1.2% yield and the average healthcare stock's yield of 1.7%.
Buy 7 Barron's Better Bets (Than T-Bills) From 15 'Safer' Of 23 September Dividend Dogs
10:10am, Sunday, 28'th Sep 2025
Seven of the top fifteen Barron's Better Bets (BBB) dividend 'dogs' - including CAG, PFE, VZ, BMY, UDR, KIM, and KEY - are attractively priced for income investors. Analyst forecasts project 17.61% to
5 Dividend Powerhouses to Buy and Never Sell
10:00am, Sunday, 28'th Sep 2025
Here's a statistic that should reshape how you think about investing: Companies that consistently raise dividends have crushed the S&P 500 by 2.5 percentage points annually since 1972. Not tech highfl
Is Pfizer Stock a Buy After Its $5 Billion GLP-1 Bet?
08:15am, Saturday, 27'th Sep 2025
The GLP-1 market has grabbed considerable attention in the past couple of years, and there's little doubt as to which pharmaceutical companies dominate this space. Eli Lilly is currently the leader, f
3 Magnificent Stocks Under $100 to Buy Right Now
06:45am, Saturday, 27'th Sep 2025
Share price has nothing to do with whether a stock is fairly valued. However, it is nonetheless an important consideration for investors on tight budgets.
Pfizer is Locking in New Growth Through a New Acquisition
04:33pm, Friday, 26'th Sep 2025
In the United States' healthcare sector, a new growth theme is emerging that nearly all companies want to capitalize on. Like artificial intelligence for technology stocks, weight loss drug manufactu
Did Pfizer Just Give Investors 7 Billion Reasons to Buy Its Stock?
08:45am, Friday, 26'th Sep 2025
In the pharmaceutical world, if you can't develop 'em, acquire 'em. That seems to be the philosophy behind Pfizer's (PFE -1.97%) latest big-ticket buy, specifically its purchase of clinical-stage biot
Eli Lilly, Pfizer Stocks Rise After Trump's 100% Pharma Tariff Threat. Here's Why.
08:15am, Friday, 26'th Sep 2025
Trump's threat of a 100% tariff on imported branded or patented drugs sounds dramatic, yet, pharma stocks were mostly in the green as the past few months have already seen a flurry of companies announ
